HLS ASX: Pathology group Healius is restructuring management and cutting costs in its largest business, as UBS presses on with strategic review

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 90%

Business News News

Business Business Latest News,Business Business Headlines

Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.

Two top executives in the group’s Queensland pathology business QML have departed in the restructure outlined in an internal email on March 27 from the boss of the Healius Pathology division, Jan Van Rooyen.

Healius, formerly known as Primary Health Care, replaced its chief executive, Maxine Jaquet, in early March after just 12 months in the job following a profit plunge and $2 billion in sharemarket value disappearing. A revival in the financial performance of the pathology division is crucial for Healius. Mr Van Rooyen was hired to run the division after having been the CEO of AMPATH in South Africa for almost 20 years, which he built into a national business after integrating several smaller operations.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in BUSİNESS

Business Business Latest News, Business Business Headlines